Know2eat

Calcium hydroxyapatite (MCHC)

Minerals

What calcium hydroxyapatite (mchc) may help with

Ranked by how strong the human evidence is — best supported first.

Best supportedBone mineral densityLimited evidence· 2 sources

About Calcium hydroxyapatite (MCHC)

Calcium supplied in the mineral form found in bone, manufactured from bovine bone and containing phosphorus, collagen fragments and trace minerals alongside the calcium. Sold on the premise that a bone-like matrix is better used by bone.

The argument for hydroxyapatite is intuitive and weakly evidenced. A small number of older European studies, mostly of ossein-hydroxyapatite complex, reported bone density effects, but the trials are dated, small and not readily compared with modern calcium research. Absorption studies have found hydroxyapatite absorbed comparably to or slightly less well than other calcium salts. The consideration that distinguishes it is sourcing: it is an animal bone product, and bone concentrates lead, which has led to repeated recommendations to check heavy-metal testing on this specific category.

Sold as
Tablet, Capsule, Ossein-hydroxyapatite complex, Combination with vitamin D and K
Also known as
Microcrystalline hydroxyapatite, MCHC, Bone-derived calcium, Ossein-hydroxyapatite

Regulation: Subject to the same calcium RDA and upper limit as any calcium source. Bone-derived supplements have historically attracted regulatory attention over lead content, and in some jurisdictions over bovine spongiform encephalopathy sourcing controls.

What the research used

The amounts, forms and durations published trials of Calcium hydroxyapatite (MCHC) actually administered.

These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.

  • Studied for Typical retail supplement

    500–1000 mg

    Not enough

    Elemental calcium from MCHC, daily

    Labels frequently state the total MCHC weight rather than elemental calcium, which overstates the calcium dose considerably. The phosphorus supplied alongside also counts toward phosphorus intake.

  • Studied for Older bone density studies

    700–1200 mg

    Limited

    Ossein-hydroxyapatite complex, daily · 1–2 years

    Small European trials from the 1980s and 1990s, with methods reported in limited detail and little modern replication.

This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.

When it was taken

Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.

None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.

  • With food

    Not enough

    Taken with meals by convention and for tolerability. No comparative timing study exists for this form.

    Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.

The evidence in depth

Best supported: Limited

What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.

Bone mineral density

Bone Health
Limited evidence

Small older trials of ossein-hydroxyapatite reported effects on bone density, and some comparisons suggested an advantage over carbonate. The studies are dated and small, absorption studies do not show superiority, and no modern fracture trial has used this form.

Limited evidence. Early human work, or mostly lab and animal research.

View the 2 sources

Deep research mode adds each paper’s own conclusion and stated limitations.

Things to know

Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.

  • Worth knowing

    Lead content in bone-derived products

    Bone accumulates lead over an animal's lifetime, and analyses of bone meal and bone-derived calcium supplements have repeatedly found measurably higher lead than other calcium salts. Third-party heavy-metal testing is worth insisting on, and these products are a poor choice in pregnancy and for children.

  • Interaction

    Same medicine interactions as other calcium salts

    Interacts withLevothyroxine, tetracyclines, fluoroquinolones, bisphosphonates, iron supplements

    Reduces absorption of levothyroxine, tetracyclines, fluoroquinolones, bisphosphonates and iron; separation by several hours is standard.

  • Too much

    Phosphorus load

    Hydroxyapatite supplies phosphorus alongside calcium. That is irrelevant for most people but matters in chronic kidney disease, where phosphate restriction is often part of management.

  • Worth knowing

    Animal sourcing

    This is a bovine bone product, unsuitable for vegetarians and vegans, and sourcing controls vary between manufacturers and countries.

Evidence ratings on this page: 1 limited evidence.

Supplements are sold in the US without pre-market review of efficacy or safety. Nothing on this page is a recommendation to take Calcium hydroxyapatite (MCHC), or a dose to follow.